On Tuesday, June 14, Endpoints News EIC John Carroll sat down with a group of biotechnology leaders to discuss the bear market for industrial stocks and how they tackled it. Here is the conversation, which has been easily edited for the sake of brevity.
Martin Meeson, sponsorship opening:
Thanks, John. Hi all. My name is Martin Meeson, I’m the CEO of Fujifilm Diosynth. For those of you who do not know Fujifilm Diosynth, we are developing clinical and commercial product upscaling, we have facilities in Europe and the USA, and around 4000 employees. We run an average of around 150 programs, so when it comes to coping in turbulent times over the last two years, we̵[ads1]7;ve had quite a bit of experience with it. Not only to keep the clinical pipelines and the commercial pipelines open, but also our response to the pandemic and the molecules we have had in there. One of the phrases I created about a year ago when we spoke on JP Morgan was that I talked about coping through turbulent times. Well, it has become the fact that we do not control and lead through these times, we manage in them, and that is why that is really the purpose and theme we have today.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.